Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genmab A/S (GMAB.CO)
Copenhagen, DK
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.45% | -6.48% | -6.90% | -11.40% | -15.21% | -16.97% | +26.25% | -41.91% | -25.30% | +66.15% | +566.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 10 | 0 |
| Hold | 3 | -2 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%-82.1% Q1'26: -82.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-86.9% Q1'26: -96.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+32.5% Q1'26: -0.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+33.6% ★ Q1'26: +25.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.7% ★ Q1'26: +13.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-3.0% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.05× Q1'26: 0.47× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 12 EPS Ana. |
Dec 2027 18 Rev. Ana. 13 EPS Ana. |
Dec 2028 14 Rev. Ana. 12 EPS Ana. |
Dec 2029 9 Rev. Ana. 10 EPS Ana. |
Dec 2030 13 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.13B
est: 161.37M (+602.1%)
|
1.82B
est: 249.08M (+629.1%)
|
2.37B
est: 364.09M (+549.7%)
|
3.03B
est: 459.24M (+558.7%)
|
5.37B
est: 756.14M (+609.7%)
|
10.11B
est: 1.61B (+529.3%)
|
8.48B
est: 1.28B (+564.7%)
|
14.60B
est: 2.05B (+613.1%)
|
16.47B
est: 2.74B (+501.7%)
|
21.53B
est: 3.00B (+618.4%)
|
3.86B
est: 3.71B (+4.1%)
|
4.26B
4.07B – 4.44B
+15.0% YoY
|
5.03B
4.56B – 5.35B
+17.9% YoY
|
6.10B
5.66B – 6.43B
+21.3% YoY
|
6.21B
5.76B – 6.54B
+1.8% YoY
|
6.45B
5.99B – 6.80B
+3.9% YoY
|
| EBITDA |
789.47M
est: 78.05M (+911.5%)
|
1.17B
est: 120.46M (+872.4%)
|
1.11B
est: 176.09M (+532.7%)
|
1.70B
est: 222.10M (+665.3%)
|
3.01B
est: 365.69M (+721.7%)
|
6.16B
est: 777.01M (+692.8%)
|
4.18B
est: 617.18M (+577.1%)
|
7.33B
est: 989.82M (+640.3%)
|
5.99B
est: 1.19B (+405.5%)
|
9.70B
est: 1.30B (+647.8%)
|
1.37B
est: 1.60B (-14.6%)
|
1.84B
1.76B – 1.92B
+15.0% YoY
|
2.18B
1.97B – 2.32B
+17.9% YoY
|
2.64B
2.45B – 2.78B
+21.3% YoY
|
2.69B
2.49B – 2.83B
+1.8% YoY
|
2.79B
2.59B – 2.94B
+3.9% YoY
|
| EBIT |
757.65M
est: 74.25M (+920.4%)
|
1.13B
est: 114.60M (+886.4%)
|
1.07B
est: 167.52M (+536.7%)
|
1.61B
est: 211.30M (+662.9%)
|
2.87B
est: 347.90M (+723.8%)
|
5.91B
est: 739.21M (+700.0%)
|
4.00B
est: 587.15M (+580.6%)
|
6.97B
est: 941.67M (+639.8%)
|
5.66B
est: 1.12B (+404.1%)
|
9.28B
est: 1.23B (+655.1%)
|
1.30B
est: 1.52B (-14.7%)
|
1.75B
1.67B – 1.82B
+15.0% YoY
|
2.06B
1.87B – 2.20B
+17.9% YoY
|
2.50B
2.32B – 2.64B
+21.3% YoY
|
2.55B
2.37B – 2.69B
+1.8% YoY
|
2.65B
2.46B – 2.79B
+3.9% YoY
|
| Net Income |
763.51M
est: 89.87M (+749.6%)
|
1.19B
est: 145.59M (+715.3%)
|
1.10B
est: 177.89M (+520.3%)
|
1.47B
est: 204.54M (+619.7%)
|
2.17B
est: 323.90M (+568.7%)
|
4.76B
est: 760.48M (+525.7%)
|
2.96B
est: 429.91M (+587.8%)
|
5.45B
est: 929.87M (+486.3%)
|
4.35B
est: 797.70M (+445.6%)
|
7.84B
est: 745.33M (+952.4%)
|
999.19M
est: 1.07B (-6.5%)
|
803.01M
598.50M – 1.01B
-24.9% YoY
|
1.04B
657.92M – 1.43B
+30.1% YoY
|
1.58B
992.27M – 2.17B
+51.2% YoY
|
1.49B
1.35B – 1.60B
-5.6% YoY
|
1.61B
1.46B – 1.73B
+8.1% YoY
|
| SGA |
91.22M
est: 25.05M (+264.1%)
|
102.41M
est: 38.67M (+164.9%)
|
146.99M
est: 56.52M (+160.1%)
|
213.70M
est: 71.29M (+199.7%)
|
342.00M
est: 117.38M (+191.4%)
|
661.00M
est: 249.41M (+165.0%)
|
1.28B
est: 198.10M (+547.6%)
|
2.68B
est: 317.72M (+742.3%)
|
3.30B
est: 477.88M (+589.9%)
|
3.79B
est: 522.94M (+624.8%)
|
624.62M
est: 646.86M (-3.4%)
|
743.94M
709.89M – 775.20M
+15.0% YoY
|
877.39M
795.73M – 933.92M
+17.9% YoY
|
1.06B
988.49M – 1.12B
+21.3% YoY
|
1.08B
1.01B – 1.14B
+1.8% YoY
|
1.13B
1.04B – 1.19B
+3.9% YoY
|
| EPS |
13.05
est: 1.39 (+838.6%)
|
19.83
est: 2.25 (+780.3%)
|
18.14
est: 2.75 (+559.1%)
|
24.03
est: 3.16 (+659.3%)
|
34.40
est: 5.01 (+586.4%)
|
73.00
est: 11.77 (+520.4%)
|
46.00
est: 6.65 (+591.6%)
|
83.38
est: 14.41 (+478.5%)
|
66.64
est: 12.25 (+443.8%)
|
122.21
est: 12.02 (+916.4%)
|
16.08
est: 17.25 (-6.8%)
|
11.19
9.55 – 16.07
-35.1% YoY
|
16.45
10.49 – 22.84
+47.0% YoY
|
25.05
15.83 – 34.59
+52.3% YoY
|
23.81
21.60 – 25.48
-5.0% YoY
|
25.73
23.34 – 27.54
+8.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer | 21M | — |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 11M | male |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 11M | male |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer | 8M | — |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 8M | — |
| Anthony Pagano | Executive Vice President & Chief Financial Officer | 7M | male |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | 6M | — |
| Christopher Cozic | Executive Vice President & Chief People Officer | 5M | male |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 2M | male |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | 2M | — |
| Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | 638.4K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GMAB.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
